CAMBRIDGE, UK, April 2, 2026
AstraZeneca has announced positive results from the Phase III EMERALD-3 trial, where a combination of Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolisation (TACE) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolisation. The findings highlight a major advancement in immunotherapy-based combination strategies aimed at improving outcomes in earlier-stage liver cancer, a disease with historically limited treatment options and high recurrence rates.
Phase III EMERALD-3 Trial Shows Strong Clinical Benefit
The global, randomized EMERALD-3 Phase III trial, conducted across 171 centers in 22 countries, evaluated the efficacy of the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) in combination with TACE, with or without lenvatinib, compared to TACE alone, the current standard of care. Results demonstrated a significant improvement in progression-free survival, the study’s primary endpoint, indicating that the addition of dual immunotherapy and targeted therapy can effectively delay disease progression.
Additionally, interim analysis showed a positive trend toward improved overall survival (OS), a key secondary endpoint, further supporting the clinical value of integrating immunotherapy earlier in treatment pathways. These findings are particularly impactful given that most patients undergoing TACE alone experience disease progression within six to ten months, underscoring the urgent need for more durable treatment approaches.
Combination Strategy Enhances Immunotherapy Impact
Advertisement
The investigational regimen combines immune checkpoint inhibitors Imfinzi (anti-PD-L1) and Imjudo (anti-CTLA-4) with lenvatinib, a multi-kinase inhibitor, alongside TACE, a localized treatment that blocks tumor blood supply and delivers chemotherapy directly to the liver. This multi-modal approach targets cancer through complementary mechanisms, including immune activation, angiogenesis inhibition, and direct tumor embolisation, creating a synergistic therapeutic effect.
The STRIDE regimen primes the immune system to attack cancer cells, while lenvatinib enhances anti-tumor activity by inhibiting vascular growth signals. The addition of TACE further disrupts tumor viability, making this combination a comprehensive strategy for managing unresectable HCC. Importantly, the safety profile of the combination remained consistent with known profiles of each component, with no new safety concerns identified, reinforcing its potential for broader clinical adoption.
Addressing High Burden of Liver Cancer Globally
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third-leading cause of cancer-related death worldwide, with more than 200,000 patients annually eligible for embolisation-based therapies. Despite existing treatments, high recurrence rates and limited survival outcomes continue to pose significant challenges, particularly in patients with unresectable disease. The EMERALD-3 results suggest that introducing immunotherapy earlier in the treatment continuum can significantly improve disease control and potentially extend survival.
AstraZeneca is now engaging with global regulatory authorities to discuss these findings, while awaiting final overall survival data. The company’s broader oncology pipeline continues to explore innovative immunotherapy combinations across multiple tumor types, reinforcing its commitment to transforming cancer care through science-driven innovation and combination therapy strategies.
With strong Phase III evidence, a novel combination approach, and the potential to reshape treatment standards in liver cancer, the Imfinzi-based regimen represents a significant breakthrough in oncology, offering new hope for patients facing one of the most aggressive and deadly cancers worldwide.
Source: AstraZeneca press release
